Gilead To License New Hepatitis C Drug To Indian Generic Drug Manufacturers
Reuters: Gilead to license hepatitis C drug to lower-cost manufacturers in India
“Gilead Sciences plans to license its breakthrough hepatitis C drug Sovaldi to a number of Indian generic pharmaceutical manufacturers, allowing for lower-priced sales of the medication in that developing nation, according to the company…” (Beasley, 2/6).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.